» Articles » PMID: 18991629

A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer

Overview
Journal Curr Med Chem
Specialty Chemistry
Date 2008 Nov 11
PMID 18991629
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

The coumarin (benzopyran-2-one, or chromen-2-one) ring system, present in natural products (such as the anticoagulant warfarin) that display interesting pharmacological properties, has intrigued chemists and medicinal chemists for decades to explore the natural coumarins or synthetic analogs for their applicability as drugs. Many molecules based on the coumarin ring system have been synthesized utilizing innovative synthetic techniques. The diversity oriented synthetic routes have led to interesting derivatives including the furanocoumarins, pyranocoumarins, and coumarin sulfamates (COUMATES), which have been found to be useful in photochemotherapy, antitumor and anti-HIV therapy, and as stimulants for central nervous system, antibacterials, anti-inflammatory, anti-coagulants, and dyes. Of particular interest in breast cancer chemotherapy, some coumarins and their active metabolite 7-hydroxycoumarin analogs have shown sulfatase and aromatase inhibitory activities. Coumarin based selective estrogen receptor modulators (SERMs) and coumarin-estrogen conjugates have also been described as potential antibreast cancer agents. Since breast cancer is the second leading cause of death in American women behind lung cancer, there is a strong impetus to identify potential new drug treatments for breast cancer. Therefore, the objective of this review is to focus on important coumarin analogs with antibreast cancer activities, highlight their mechanisms of action and structure-activity relationships on selected receptors in breast tissues, and the different methods that have been applied in the construction of these pharmacologically important coumarin analogs.

Citing Articles

Recent Perspectives on Anticancer Potential of Coumarin Against Different Human Malignancies: An Updated Review.

Shahbaz M, Perween A, Momal U, Imran M, Ul Hassan M, Naeem H Food Sci Nutr. 2025; 13(1):e4696.

PMID: 39803273 PMC: 11717051. DOI: 10.1002/fsn3.4696.


AI Based Discovery of a New AKR1C3 Inhibitor for Anticancer Applications.

Pippione A, Vigato C, Tucciarello C, Hussain S, Salladini E, Truong H ACS Med Chem Lett. 2024; 15(8):1269-1278.

PMID: 39140045 PMC: 11318022. DOI: 10.1021/acsmedchemlett.4c00150.


Combining In Vitro, In Vivo, and Network Pharmacology Assays to Identify Targets and Molecular Mechanisms of Spirulina-Derived Biomolecules against Breast Cancer.

Hassanin S, Mohmmed Hegab A, Mekky R, Said M, Khalil M, Hamza A Mar Drugs. 2024; 22(7).

PMID: 39057437 PMC: 11278317. DOI: 10.3390/md22070328.


Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy.

Zhu S, Zhu W, Zhao K, Yu J, Lu W, Zhou R Cell Commun Signal. 2024; 22(1):361.

PMID: 39010083 PMC: 11247895. DOI: 10.1186/s12964-024-01733-4.


Synthesis and antiproliferative evaluation of novel 3,5,8-trisubstituted coumarins against breast cancer.

Salem M, Alqahtani A, Mali S, Alshwyeh H, Jawarkar R, Altamimi A Future Med Chem. 2024; 16(11):1053-1073.

PMID: 38708686 PMC: 11216633. DOI: 10.4155/fmc-2023-0375.


References
1.
MARSHALL M, Mohler J, Edmonds K, Williams B, Butler K, Ryles M . An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin. J Cancer Res Clin Oncol. 1994; 120 Suppl:S39-42. DOI: 10.1007/BF01377124. View

2.
Stanchev S, Momekov G, Jensen F, Manolov I . Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives. Eur J Med Chem. 2007; 43(4):694-706. DOI: 10.1016/j.ejmech.2007.05.005. View

3.
Pollard I, Martin L . The oestrogenic and anti-oestrogenic activity of some synthetic steroids and non-steroids. Steroids. 1968; 11(6):897-907. DOI: 10.1016/s0039-128x(68)80103-5. View

4.
Castiglione-Gertsch M . New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity. Eur J Cancer. 1996; 32A(3):393-5. DOI: 10.1016/0959-8049(95)00013-5. View

5.
Kirkiacharian S, Lormier A, Resche-Rigon M, Bouchoux F, Cerede E . [Synthesis and binding affinity of 3-aryl-7-hydroxycoumarins to human alpha and beta estrogen receptors]. Ann Pharm Fr. 2003; 61(1):51-6. View